We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter summarizes current knowledge about chronic thromboembolic pulmonary hypertension (CTEPH), and discusses the perioperative and anesthetic management of patients scheduled for pulmonary endarterectomy (PEA). It discusses the pathophysiology, prognosis, diagnosis, and treatment for CTEPH. Approximately half of the patients exhibit known thrombotic tendencies like protein-C deficiency, factor V Leiden deficiency, anti-phospholipid syndrome or other autoimmune disorders. Computerized tomography scanning with pulmonary angiography is a useful tool in distinguishing between proximal and distal disease. The peri-operative management of patients undergoing pulmonary endarterectomy is complex and involves a multidisciplinary team of physicians, surgeons, anesthetists and intensivists. Thorough preoperative investigation and ascertaining the appropriateness of surgery is essential. Generally quoted and accepted peri-operative mortality risk is 10%, down to 4% in centers with large experience. In most surviving patients, a marked reduction in the pulmonary arterial pressure is observed and right heart function will return to normal within a few months.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.